Patents by Inventor Young Il Yeom
Young Il Yeom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210361694Abstract: The present invention relates to a method for preventing or treating cancer comprising administering a Synaptotagmin 11 (SYT11) inhibitor to a subject, a method for diagnosing cancer comprising measuring an expression level of SYT11, and a method for screening a preparation for treating cancer.Type: ApplicationFiled: April 19, 2021Publication date: November 25, 2021Inventors: Jae Ho CHEONG, Mi Sun WON, Bo Kyung KIM, Hyun Seung BAN, Kyung Chan PARK, Young Il YEOM
-
Patent number: 9217149Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.Type: GrantFiled: September 3, 2014Date of Patent: December 22, 2015Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Misun Won, Kyung-Sook Chung, Young Joo Kim, Hye Kyung Hong, Young Il Yeom, Chae Ok Yun, Yu-Kyoung Oh, Kyung Bin Song, Hee Gu Lee, Eun Young Song, Young Ho Kim, Moon Hee Kim, Kyeong-Eun Jung
-
Patent number: 9075066Abstract: The present invention relates to a biomarker for gastric cancer, CST1 (cysteine proteinase inhibitor, type 2 family), DCC1 (Defective in sister chromatid cohesion homolog 1), IFITM1 (interferon induced transmembrane protein 1) or MELK (maternal embryonic leucine zipper kinase). More particularly, the present invention relates to a diagnostic composition for gastric cancer comprising an agent measuring the expression level of CST1, DCC1, IFITM1 or MELK, a kit comprising the composition, a method for detecting the marker, and a method for screening a therapeutic agent for gastric cancer using the marker.Type: GrantFiled: April 21, 2009Date of Patent: July 7, 2015Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Hee Gu Lee, Eun Young Song, Min Ah Kang, Jong Tae Kim, Jae Wha Kim, Young Il Yeom, Seon Young Kim, Kyung Chan Park
-
Patent number: 9034327Abstract: Disclosed are novel GPCR (G Protein Coupled Receptor) proteins and genes encoding the same. Also provided is the use of the proteins and the genes. Particularly, contemplated are a novel GPCR (G Protein Coupled Receptor) polypeptide, a polynucleotide coding for the same, a recombinant vector carrying the polynucleotide or a fragment thereof, host cells transformed with the vector, a transgenic animal infected with the vector. Also, a composition for detecting a cancer marker, comprising an agent capable of measuring the expression level of mRNA or protein of the GPCR polynucleotide, a kit for the diagnosis of cancer, comprising the composition, and a method for detecting the GPCR polypeptide and a gene encoding the polypeptide are provided.Type: GrantFiled: September 7, 2009Date of Patent: May 19, 2015Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Kyung Sook Chung, Mi Sun Won, Ji Won Ahn, Jeong Hae Choi, Hyang Sook Yoo, Young Il Yeom, Eun Young Song, Hee Gu Lee, Jae Hun Cheong, Chang Mo Kang
-
Publication number: 20140371300Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.Type: ApplicationFiled: September 3, 2014Publication date: December 18, 2014Inventors: Misun Won, Kyung-Sook Chung, Young Joo Kim, Hye Kyung Hong, Young Il Yeom, Chae Ok Yun, Yu-Kyoung Oh, Kyung Bin Song, Hee Gu Lee, Eun Young Song, Young Ho Kim, Moon Hee Kim, Kyeong-Eun Jung
-
Patent number: 8846630Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.Type: GrantFiled: November 1, 2010Date of Patent: September 30, 2014Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Misun Won, Kyung-Sook Chung, Young Joo Kim, Hye Kyung Hong, Young Il Yeom, Chae Ok Yun, Yu-Kyoung Oh, Kyung Bin Song, Hee Gu Lee, Young Ho Kim, Moon Hee Kim, Kyeong-Eun Jung, Seok Hoon Song
-
Patent number: 8809295Abstract: The present invention relates to a composition comprising an inhibitor of the expression or activity of SH3 domain containing ring finger 2 (SH3RF2) for preventing or treating cancers. More specifically, since the SH3RF2 protein, of which the expression level increases in various cancer tissues, binds to PAK4, which is a cancer-associated gene, to regulate an apoptosis inhibitory function of the PAK4 protein by ubiquitination activity of SH3RF2 RING domain, cancer cells, in which the expression of SH3RF2 is inhibited, sensitively respond to the induction of apoptosis to promote apoptosis and reduce in vivo tumorigenicity, such that the inhibitor of the expression or activity of SHRF2 can be useful as a composition for preventing or treating cancers.Type: GrantFiled: January 7, 2011Date of Patent: August 19, 2014Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Kyung Chan Park, Young Il Yeom, Tae Woo Kim, Zee-Yong Park, Yun Kyung Kang, Suk-Jin Yang, Byung-Jung Choi, Dong Chul Lee, Hyun Ahm Shon, Hyang-Sook Yoo
-
Patent number: 8703419Abstract: The present invention relates to a method for the diagnosis and prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP (Tristetraprolin) promoter and treatment of cancers by regulating its epigenetic status. Particularly, the present invention relates to a method for the diagnosis and prognosis of liver cancer by measuring specific methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41, and a method for treatment of cancer by regulating the same. The present invention can be effectively used for the diagnosis and/or treatment of liver cancer characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41. The present invention can be further applied for the diagnosis and treatment of other cancers or inflammatory diseases that are characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID.Type: GrantFiled: September 8, 2010Date of Patent: April 22, 2014Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Young Il Yeom, Bo Hwa Sohn, In Young Park, Jung Ju Lee, Yejin Jang, Suk-jin Yang, Kyung Chan Park, Hyang-sook Yoo, Jong Young Choi
-
Patent number: 8486905Abstract: Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.Type: GrantFiled: December 5, 2008Date of Patent: July 16, 2013Assignees: Korea Research Institute of Bioscience and Biotechnology, St. Pharm Co., Ltd.Inventors: Misun Won, Kyung-Sook Chung, Young-Joo Kim, Shin-Jung Choi, Young Il Yeom, Seon-Young Kim, Kyung Bin Song, Hee Gu Lee, Eun Young Song, Young Ho Kim, Ho Kyung Chun, Chae-Ok Yun, Moon Hee Kim, Kyeong-Eun Jung, Sun-Jung Cho
-
Publication number: 20130028957Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.Type: ApplicationFiled: November 1, 2010Publication date: January 31, 2013Inventors: Misun Won, Kyung-Sook Chung, Young Joo Kim, Hye Kyung Hong, Young Il Yeom, Chae Ok Yun, Yu-Kyoung Oh, Kyung Bin Song, Hee Gu Lee, Young Ho Kim, Moon Hee Kim, Kyeong-Eun Jung, Seok Hoon Song
-
Publication number: 20120321635Abstract: The present invention relates to a composition comprising an inhibitor of the expression or activity of SH3 domain containing ring finger 2 (SH3RF2) for preventing or treating cancers. More specifically, since the SH3RF2 protein, of which the expression level increases in various cancer tissues, binds to PAK4, which is a cancer-associated gene, to regulate an apoptosis inhibitory function of the PAK4 protein by ubiquitination activity of SH3RF2 RING domain, cancer cells, in which the expression of SH3RF2 is inhibited, sensitively respond to the induction of apoptosis to promote apoptosis and reduce in vivo tumorigenicity, such that the inhibitor of the expression or activity of SHRF2 can be useful as a composition for preventing or treating cancers.Type: ApplicationFiled: January 7, 2011Publication date: December 20, 2012Inventors: Kyung Chan Park, Young Il Yeom, Tae Woo Kim, Zee-Yong Park, Yun Kyung Kang, Suk-Jin Yang, Byung-Jung Choi, Dong Chul Lee, Hyun Ahm Shon, Hyang-Sook Yoo
-
Patent number: 8283129Abstract: Disclosed herein is a colorectal cancer marker for diagnosing colorectal cancer based on ESM-I overexpression in tissues, cells or body fluids of colorectal cancer patients. Disclosed also is the use of the colorectal cancer marker in the development of therapeutic agents for cancer and in the diagnosis and treatment of colorectal cancer.Type: GrantFiled: November 23, 2007Date of Patent: October 9, 2012Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Eun Young Song, Mi Young Park, Hyang Sin Lee, Hee Gu Lee, Jae Wha Kim, In Seong Choe, Min A Kang, Mi Sun Won, Kyung-Sook Chung, Young Ho Kim, Ho Kyung Chun, Young Il Yeom, Seon-Young Kim
-
Publication number: 20120251499Abstract: The present invention relates to a method for the diagnosis and prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP (Tristetraprolin) promoter and treatment of cancers by regulating its epigenetic status. Particularly, the present invention relates to a method for the diagnosis and prognosis of liver cancer by measuring specific methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41, and a method for treatment of cancer by regulating the same. The present invention can be effectively used for the diagnosis and/or treatment of liver cancer characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID. NO. 41. The present invention can be further applied for the diagnosis and treatment of other cancers or inflammatory diseases that are characterized by TTP down-regulation and methylation of C, the 32nd residue of the nucleic acid sequence represented by SEQ. ID.Type: ApplicationFiled: September 8, 2010Publication date: October 4, 2012Inventors: Young Il Yeom, Bo Hwa Sohn, In Young Park, Jung Ju Lee, Yejin Jang, Suk-jin Yang, Kyung Chan Park, Hyang-sook Yoo, Jong Young Choi
-
Publication number: 20120141488Abstract: Disclosed are novel GPCR (G Protein Coupled Receptor) proteins and genes encoding the same. Also provided is the use of the proteins and the genes. Particularly, contemplated are a novel GPCR (G Protein Coupled Receptor) polypeptide, a polynucleotide coding for the same, a recombinant vector carrying the polynucleotide or a fragment thereof, host cells transformed with the vector, a transgenic animal infected with the vector. Also, a composition for detecting a cancer marker, comprising an agent capable of measuring the expression level of mRNA or protein of the GPCR polynucleotide, a kit for the diagnosis of cancer, comprising the composition, and a method for detecting the GPCR polypeptide and a gene encoding the polypeptide are provided.Type: ApplicationFiled: September 7, 2009Publication date: June 7, 2012Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHInventors: Kyung Sook Chung, Mi Sun Won, Ji Won Ahn, Jeong Hae Choi, Hyang Sook Yoo, Young Il Yeom, Eun Young Song, Hae Gu Lee, Jae Hun Cheong, Chang Mo Kang
-
Publication number: 20110251097Abstract: The present invention relates to a composition for diagnosing colon cancer. The composition comprises at least one marker for measuring an mRNA or protein expression level of at least one gene specific for colon cancer. It can screen the genes which are overexpressed specifically only in colon cancer tissues or blood. The present invention can quantitatively analyze both the mRNA expression levels of the genes and the expression levels of the proteins encoded by the gene at the same time, thereby diagnosing colon caner of an early stage with a high level of reliability.Type: ApplicationFiled: April 20, 2009Publication date: October 13, 2011Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Eun Young Song, Hee Gu Lee, Young Il Yeom, Jae Wha Kim, Na Young Ji, Kyung-Sook Chung, Misun Won, Seon-Young Kim, Joo Heon Kim, Young Ho Kim, Ho Kyung Chun
-
Publication number: 20110008370Abstract: Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.Type: ApplicationFiled: December 5, 2008Publication date: January 13, 2011Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHInventors: Misun Won, Kyung-Sook Chung, Young-Joo Kim, Shin-Jung Choi, Young Il Yeom, Seon-Young Kim, Kyung Bin Song, Hee Gu Lee, Eun Young Song, Young Ho Kim, Ho Kyung Chun, Chae-Ok Yun, Moon Hee Kim, Kyeong-Eun Jung, Sun-Jung Cho
-
Publication number: 20100248244Abstract: Disclosed herein is a colorectal cancer marker for diagnosing colorectal cancer based on ESM-I overexpression in tissues, cells or body fluids of colorectal cancer patients. Disclosed also is the use of the colorectal cancer marker in the development of therapeutic agents for cancer and in the diagnosis and treatment of colorectal cancer.Type: ApplicationFiled: November 23, 2007Publication date: September 30, 2010Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Eun Young Song, Mi Young Park, Hyang Sin Lee, Hee Gu Lee, Jae Wha Kim, In Seong Choe, Min A. Kang, Mi Sun Won, Kyung Sook Chung, Young Ho Kim, Ho Kyung Chun, Young Il Yeom, Seon-Young Kim
-
Publication number: 20100203510Abstract: Disclosed is a marker for diagnosis of liver cancer comprising polynucleotide useful for diagnosis of liver cancer. The marker for liver cancer diagnosis comprises at least one polynucleotide selected from a group consisting of the following polynucleotides (a) to (d):(a) polynucleotide having a base sequence defined by Seq. No. 1 or substantially similar sequence to Seq. No. 1; (b) polynucleotide encoding specific protein composed of an amino acid sequence defined by Seq. No. 2; (c) polynucleotide that comprises Seq. No. 2, in which at least one amino acid is substituted, deleted, inserted and/or added, and that encodes protein functionally equivalent to specific protein composed of Seq. No. 2; and (d) polynucleotide that is encoded by another polynucleotide hybridized with polynucleotide having Seq. No. 1 under stringent conditions, and that encodes protein functionally equivalent to specific protein composed of Seq. No. 2.Type: ApplicationFiled: February 10, 2009Publication date: August 12, 2010Applicants: Industrial Cooperation Foundation Chonbuk National University, Korea Research Institute Of Bioscience And BiotechnologyInventors: Dae-Ghon Kim, Gyung-Ran Yu, Eun-Young Song, Hee-Gu Lee, Young-Il Yeom, Jung-Il Lee, Jae-Wha Kim, Na-Young Ji
-
Patent number: 7718780Abstract: The present invention relates to a monoclonal antibody specific for N-myc downstream regulated gene 2 (NDRG 2) protein, a cell line producing the monoclonal antibody, a method for measuring a quantity and quality of NDRG 2 protein, and a protein chip using the same. In the present invention, NDRG 2, a cancer-related factor is specifically expressed in dendritic cells differentiated from a monocyte of human peripheral blood. Accordingly, the monoclonal antibody specific for the NDRG 2 protein, the protein chip comprising the same and the method for measuring a quantity and quality of the NDRG 2 protein by using the same can be applied to elucidate characteristics of the dendritic cell and perform a research on the NDRG 2. Therefore, the present invention may help clinically to investigate and treat intractable diseases and cancers using the dendritic cell.Type: GrantFiled: March 31, 2006Date of Patent: May 18, 2010Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Eun Young Song, Jae Wha Kim, Hee Gu Lee, Jong Seok Lim, Seung Chul Choi, Mi Young Cho, Kyoung Eun Baek, Jin Sook Kim, Jong Tae Kim, Do Young Yoon, Dur Han Kwon, Mi-Young Park, Young Il Yeom, Yong-Kyung Choe, Young-Jun Kim
-
Publication number: 20090130694Abstract: Disclosed is a diagnostic kit for gastric cancer. It comprises an agent capable of detecting and quantitatively assaying the gastric cancer marker Mac-2BP (Mac-2 binding protein). Also, a method for detecting the gastric cancer marker using the kit is disclosed.Type: ApplicationFiled: September 25, 2006Publication date: May 21, 2009Inventors: Hee Gu Lee, Yuk Pheel Park, Jae Wha Kim, Eun Young Song, Do Young Yoon, Young Il Yeom, Seung-Chul Choi